Lizhu Group (Ningxia) expands its enzyme phenolic acid production capacity to 800 tons per year

Thread Content

Recently, information regarding the enzyme phenolic acid technology upgrade project of Livzon Group (Ningxia) Pharmaceutical Co., Ltd. was made public on relevant websites. Basic project information: Project name: Enzyme Phenolic Acid Technology Upgrade Project of Livzon Group (Ningxia) Pharmaceutical Co., Ltd ； Construction unit: Lizhu Group (Ningxia) Pharmaceutical Co., Ltd ； Construction location: Ningxia Pingluo Industrial Park, Shizuishan City ； Nature of construction: technical renovation ； Total investment: 30 million yuan ； Construction contents: Upgrade the existing fermentation strains and improve the ratio of fermentation raw materials. Add relevant supporting facilities such as seed tanks, fermentation tanks, filters, and transfer tanks to the existing mycophenolate fermentation and purification workshops. Replace some equipment such as transfer tanks; the utility systems, auxiliary facilities, and environmental protection systems will make use of the existing infrastructure. Construction scale: Technical upgrades will be carried out on the existing production line, increasing the production capacity from 250 tons per year to 800 tons per year. Furthermore, according to publicly available information, a project at Jiaozuo Health Yuan Biology aimed at producing 300 tons of mycophenolic acid per year was announced on relevant websites recently. Lizhu Group’s mycophenolic acid is produced using a fermentation-extraction-purification process; it holds FDA approval and GMP certifications, boasts stable product quality, and is exported to over 20 countries including the United States, Europe, and Japan. It is one of the company’s key specialty active pharmaceutical ingredients. Mycophenolic acid is the key starting material for immunosuppressants; it is not used directly to formulate drugs. Instead, it is converted into mycophenolate mofetil through esterification reactions, and into mycophenolate sodium through salt formation, after which it is further used to produce capsules, tablets, enteric-coated tablets, and injections ； It is primarily used to prevent rejection after organ transplantation and to treat autoimmune diseases, and it is an essential bulk active pharmaceutical ingredient in the field of transplantation. Lizhu Group (Ningxia) Pharmaceutical Co., Ltd. is a bio-fermentation active pharmaceutical ingredient production facility established by Lizhu Group in the Pingluo Industrial Park in Ningxia. Founded in 2011, it focuses on the research, development, production, and sales of high-value-added specialty active pharmaceutical ingredients. With biofermentation technology at its core, the company operates multiple production lines for products such as L-phenylalanine, mevastatin, lovastatin, mycophenolic acid, and doramectin.